15.04.2014 • News

German States May Opt out of GMO Maize

As Germany's federal government has apparently decided not to opt out of planting the genetically manipulated maize Pioneer 1507, expected to be approved by the European Commission soon, some of the country's federal states (Bundesländer) may attempt to do so.

In February of this year, Germany paved the way for EU approval of the GMO crop by abstaining from a vote in the Council of Ministers. Without a majority against the approval, the Commission is free to make its own decision and this is expected to be in favor.

Opponents of the maize developed by seeds producer Pioneer in cooperation with chemical multinational DuPont received support on Apr. 11 as the chamber of the German states, Bundesrat, voted in favor of state-level action.

Chancellor Angela Merkel is said to have dropped her opposition to GMO maize. France, however, has issued a decree banning plantings. Under current EU rules, a national opt-out is only possible if the crop is determined to be a threat to the environment or human health or if a majority of member states votes to allow the procedure.

EU consumer affairs commissioner Neven Mimica said recently that, as support for a decision at national level is growing, an opt-out clause could become reality by this autumn.

If this does happen and the states are allowed to opt out, Pioneer 1507 could not be planted in Germany at all. Any approval by the EU would come too late for planting in 2014 and would likely take effect before the planting season in 2015, the federal agriculture ministry has said.

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.